Skip to main content

1 Result(s)

within Hua-rui Xue Remove this filter

and

  1. No Access

    Article

    Structural basis of tolvaptan binding to the vasopressin V2 receptor

    The vasopressin V2 receptor (V2R) is a validated therapeutic target for autosomal dominant polycystic kidney disease (ADPKD), with tolvaptan being the first FDA-approved antagonist. Herein, we used Gaussian accel...

    Hong-li Liu, Hai-yang Zhong, Yi-xiao Zhang, Hua-rui Xue… in Acta Pharmacologica Sinica (2024)